valsartan has been researched along with Hyperglycemia, Postprandial in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Abdo, VB; Ashour, RH; Elshenawy, DSA; Ramadan, NM | 1 |
| Chang, KH; Dikalova, AE; Engberding, N; Griendling, KK; Jo, H; Koga, M; Lassègue, B; Long, JS; Seidel-Rogol, B | 1 |
| Aoyama, I; Bomsztyk, K; Komers, R; Koopmeiners, JS; Naito, M; Schnaper, HW; Shenoy, A | 1 |
| Fliser, D; Frank, H; Heemann, U; Pscherer, S | 1 |
| Huang, J; Matavelli, LC; Siragy, HM | 1 |
| Ofili, EO; Purkayastha, D; Samuel, R; Sowers, JR; Zappe, DH | 1 |
| Chan, P; Cheng, JT; Liu, IM; Tzeng, TF; Wong, KL; Yang, TL | 1 |
| Dallinga-Thie, GM; de Koning, EJ; Gaillard, CA; Rabelink, TJ; van Zonneveld, AJ; Westerink, JW; Willemsen, JM | 1 |
1 trial(s) available for valsartan and Hyperglycemia, Postprandial
| Article | Year |
|---|---|
Antihypertensive and metabolic effects of Angiotensin receptor blocker/diuretic combination therapy in obese, hypertensive African American and white patients.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Black or African American; Blood Glucose; Diuretics; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hyperglycemia; Hypertension; Insulin; Intention to Treat Analysis; Male; Middle Aged; Obesity, Abdominal; Prediabetic State; Tetrazoles; Treatment Outcome; Valine; Valsartan; White People | 2013 |
7 other study(ies) available for valsartan and Hyperglycemia, Postprandial
| Article | Year |
|---|---|
Sacubitril/valsartan combination enhanced cardiac glycophagy and prevented the progression of murine diabetic cardiomyopathy.
Topics: Aminobutyrates; Animals; Biphenyl Compounds; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Drug Combinations; Glycogen; Heart Failure; Hyperglycemia; Mice; Rats; Stroke Volume; Tetrazoles; Valsartan | 2022 |
The bone morphogenic protein inhibitor, noggin, reduces glycemia and vascular inflammation in db/db mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Blood Pressure; Bone Morphogenetic Proteins; Carrier Proteins; Diabetes Mellitus, Type 2; Disease Models, Animal; Hyperglycemia; Male; Mice; Mice, Mutant Strains; Reactive Oxygen Species; Tetrazoles; Valine; Valsartan; Vasculitis | 2013 |
High ambient glucose augments angiotensin II-induced proinflammatory gene mRNA expression in human mesangial cells: effects of valsartan and simvastatin.
Topics: Angiotensin II; Gene Expression Regulation; Glucose; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Inflammation; Kidney; Mesangial Cells; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Simvastatin; Tetrazoles; Valine; Valsartan | 2009 |
Effect of experimental hyperglycaemia on renal haemodynamics in prediabetic patients with and without AT1 receptor blockade.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Case-Control Studies; Glomerular Filtration Rate; Glucose Tolerance Test; Humans; Hyperglycemia; Male; Middle Aged; Prospective Studies; Receptor, Angiotensin, Type 1; Renal Circulation; Tetrazoles; Treatment Outcome; Valine; Valsartan; Young Adult | 2010 |
Renal (pro)renin receptor contributes to development of diabetic kidney disease through transforming growth factor-β1-connective tissue growth factor signalling cascade.
Topics: Animals; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glucose; Hyperglycemia; Male; Mesangial Cells; Oligopeptides; Prorenin Receptor; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptors, Cell Surface; RNA, Small Interfering; Signal Transduction; Tetrazoles; Transforming Growth Factor beta1; Up-Regulation; Valine; Valsartan | 2011 |
Antihyperglycemic action of angiotensin II receptor antagonist, valsartan, in streptozotocin-induced diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Glucose; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Disease Models, Animal; Gene Expression; Glucose Tolerance Test; Glucose Transporter Type 4; Hyperglycemia; Liver; Male; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Nicorandil; Nifedipine; Phosphoenolpyruvate Carboxykinase (GTP); Rats; Rats, Wistar; RNA, Messenger; Saralasin; Tetrazoles; Valine; Valsartan | 2003 |
Angiotensin II type 1 receptor blockade improves hyperglycemia-induced endothelial dysfunction and reduces proinflammatory cytokine release from leukocytes.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cytokines; Endothelium; Humans; Hyperglycemia; Inflammation Mediators; Leukocytes; Male; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan | 2007 |